Remove 2029 Remove Chemotherapy Remove Compounding
article thumbnail

Venus Remedies gets marketing approval for gemcitabine and docetaxel from Serbia

Express Pharma

Venus Remedies has secured marketing authorisation from Serbia for gemcitabine and docetaxel, widely used chemotherapy drugs. billion by 2029 at a compounded annual growth rate (CAGR) of 8.2 With this, the company has secured 511 marketing approvals for its oncology products across 66 countrles. per cent from 2021 to 2030.

article thumbnail

Eisai joins the ADC golden rush

Pharmaceutical Technology

The agent is a human epidermal growth factor receptor 2 (HER2)-targeting ADC that utilises Eisai’s chemotherapy Halaven (eribulin) as its payload. GlobalData analyst consensus forecasts project sales to reach $11.5bn by 2029, a 29% compound annual growth rate (CAGR). targeting ADC.